.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Chubb
Harvard Business School
Farmers Insurance
McKinsey
Cerilliant
Cantor Fitzgerald
US Department of Justice
Merck

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,142,051

« Back to Dashboard

Claims for Patent: 5,142,051

Title: N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity
Abstract:This invention relates to new nucleotide analogues and solves the technical problem of their use as biologically active compounds. The subject of this invention are N-(2-phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonylmethoxypropyl) derivatives of pyrimidine and purine bases, easily accessible from heterocyclic bases andd their N-(2-hydroxyethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds, according to this invention, exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.
Inventor(s): Holy; Antonin (Horni Pocernice, CS), Rosenberg; Ivan (Praha, CS), De Clercq; Erik D. A. (Leuven, BE)
Assignee: Ceskoslovenska Akademie Ved (Praha, CS) Rega Institut (Leuven, BE)
Application Number:07/074,900
Patent Claims: 1. A compound of the formula ##STR3## wherein B is selected from the group consisting of uracil-1-yl,

cytosin-1-yl,

5-methylcytosin-1-yl,

thymin-1-yl,

5-fluoruracil-1-yl,

guanin-9-yl,

guanin-7-yl,

adenin-3-yl,

hypoxanthin-9-yl,

2-methyladenin-9-yl,

2-methylthioadenin-9-yl,

2-aminoadenin-9-yl,

2-aminopurin-9-yl,

N.sup.6 -dimethyladenin-9-yl,

8-bromoadenin-9-yl,

8-hydroxyadenin-9-yl,

6-hydroxylaminopurin-9-yl,

6-hydrazinopurin-9-yl,

6-thiopurin-9-yl,

purin-9-yl, and

xanthin-9-yl.

2. The compound of claim 1, wherein B is selected from the group consisting of uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymin-1-yl, and 5-fluorouracil-1-yl.

3. The compound of claim 2, wherein B is cytosin-1-yl.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Cipla
McKinsey
QuintilesIMS
Fuji
Baxter
Medtronic
Cantor Fitzgerald
Citi
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot